Wednesday, August 19, 2026

10 days
Merck and Moderna report positive phase‑3 melanoma vaccine results (14) hot
INTerpath-001: phase‑3 vaccine reduces melanoma recurrence
Market surge: Moderna's stock jumps after trial news
Experts weigh in on personalized mRNA cancer vaccines


In Detail Full day, Wednesday, August 19, 2026, Timezone: America/Chicago

Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma

oncodaily - Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB-IV […]

AI Summary: Merck and Moderna announced that their mRNA-based melanoma vaccine, given with Keytruda, met key phase‑3 endpoints — reducing recurrence and distant metastasis after resection. The data suggest the vaccine can prime anti‑tumor immunity to prevent relapse, positioning it as a potential adjunct to standard checkpoint inhibition in high‑risk patients.


Experts weigh in on personalized mRNA cancer vaccines

Paolo A. Ascierto: Positive Phase 3 KEYTRUDA Results Advance Personalized Melanoma Treatment

8 days / oncodaily

Marco Donia: First Positive Phase 3 Trial of a Personalized Neoantigen Therapy in Cancer

8 days / oncodaily

INTerpath-001 Trial: Personalized mRNA Cancer Vaccine for Melanoma

9 days / oncodaily

Will personalised mRNA vaccines transform cancer treatments?

9 days / newscientist / Michael Le Page


INTerpath-001: phase‑3 vaccine reduces melanoma recurrence

Moderna and Merck Announce Positive Phase 3 INTerpath-001 Results in Melanoma

9 days / oncodaily

Vaccine breakthrough stops cancer returning in trial

10 days / bbc

Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma

10 days / medcitynews / Frank Vinluan

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

10 days / nytimes / Carolyn Y. Johnson

Merck, Moderna claim 'promising' skin cancer vaccine results in key trial

10 days / medicalxpress

Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma

10 days / oncodaily


Market surge: Moderna's stock jumps after trial news

Moderna’s Shift to Cancer Company Lifts Stock Up 177%

9 days / nytimes / Rebecca Robbins

Noubar Afeyan: Moderna and Merck Announce Positive Phase 3 Results in Melanoma

10 days / oncodaily

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

10 days / abcnews


All Other Stories

Rob Davis: Individualized Neoantigen Therapy Transforms Adjuvant Melanoma Care

9 days / oncodaily







StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Novo Nordisk, Alzheimer's disease, Medicare Advantage (not listed), Pediatric Oncology and look for the RSS link.

More StackHealth



Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.